NCT04345913 2026-03-19
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
7 trialsNCT03424005 2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT07007559 2026-02-03
ASPEN-09
ALX Oncology Inc.
Phase 1/2 Recruiting
NCT04711824 2025-12-23
SOLARA
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT03526679 2025-12-05
LEADER
National Taiwan University Hospital
Phase 1/2 Completed
NCT00365157 2025-07-11
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05041101 2025-06-13
Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated